Comorbidity of substance misuse and mental illness in community mental health and substance misuse services


Background Improved management of mental illness and substance misuse comorbidity is a National Health Service priority, but little is known about its prevalence and current management.

Aims To measure the prevalence of comorbidity among patients of community mental health teams (CMHTs) and substance misuse services, and to assess the potential for joint management.

Method Cross-sectional prevalence survey in four urban UK centres.

Results Of CMHT patients, 44% (95% CI 38.1–49.9) reported past-year problem drug use and/or harmful alcohol use; 75% (95% CI 68.2–80.2) of drug service and 85% of alcohol service patients (95% CI 74.2–93.1) had a past-year psychiatric disorder. Most comorbidity patients appear ineligible for cross-referral between services. Large proportions are not identified by services and receive no specialist intervention.

Conclusions Comorbidity is highly prevalent in CMHT, drug and alcohol treatment populations, but may be difficult to manage by cross-referral psychiatric and substance misuse services as currently configured and resourced.

Declaration of interest None. Funding detailed in Acknowledgements.

METHOD

Study aims
Our study aims were to measure the prevalence of comorbidity among patients of CMHTs and substance misuse services in four inner-city treatment centres, to assess whether there were differences in the prevalence between centres, and to measure the potential for joint management by CMHT and substance misuse services where patients with comorbidity were identified.

Design and setting
We conducted a cross-sectional prevalence survey between January 2001 and February 2002 in four urban UK centres. These were two neighbouring inner-London boroughs (Brent, and Hammersmith and Fulham) and services in inner-city areas of Nottingham and Sheffield. At all four centres the CMHTs were consultant-led, multi-disciplinary teams serving geographically defined catchment areas. Each had access to designated in-patient beds, operated according to contemporary care programme approach (CPA) guidelines and gave priority (in terms of the allocation of case-load places) to patients with severe and enduring mental illness. The drug and alcohol teams were statutory providers. They offered separate structured, appointment-based services through keyworkers within nurse-led clinics. All clients were allocated a personal keyworker and assigned to the case-load of a psychiatrist or responsible medical officer (RMO). All drug services had a strong emphasis upon the management of opiate dependency. Independent drug services were available in some areas (including services for stimulant users), but not in others. These latter agencies were not investigated. In each population, we completed a case-load census to identify the sampling frame and a patient interview survey with case-note audit in a random sample.

Participants
All patients of the drug and alcohol teams who were allocated to the case-load of a keyworker and psychiatrist/RMO on the census date were included in the substance misuse case-load census population. The only current patients excluded were a small proportion who had not completed an assessment. The sample sizes were proportionate to the size of the total treatment populations in each centre. To be included in the CMHT case-load census population, patients had to be allocated to the case-load of a care coordinator and psychiatrist/RMO on the census date, be aged 16–64 years and be included on the local CPA register. Only a small proportion of current CMHT patients were excluded because they had not completed an assessment, or exceeded the age range. Interview samples of 400 CMHT and 353 substance misuse patients were selected from these census populations at the coordinating centre (Imperial College) using Statistical Package for the Social Sciences (SPSS) random case selection procedures (SPSS, 1999).

Data collection
Data collection procedures were agreed with local research ethics committees. Services identified eligible patients, who were allocated anonymous case numbers used in all data collection. Care coordinators and keyworkers completed...
census questionnaires (one per patient), gave patients sampled for interview an information sheet, and invited them to meet a trained fieldworker. All interviewed patients gave written informed consent. Non-consenting patients were regarded as non-respondents and not substituted.

**Assessments**

**Case-load census**

Care coordinators and keyworkers were asked to report demographic details, ICD-10 psychiatric diagnoses (World Health Organization, 1992) established or confirmed by psychiatric assessment in the past year, and any psychiatric and substance misuse interventions provided in the past month. Care coordinators for CMHT patients were asked to identify people using any illicit or non-prescribed drug in the past year, and to apply diagnostic criteria (reproduced on the census form) to this group to identify those misusing drugs (American Psychiatric Association, 1994).

Care coordinators applied the same criteria to all patients to identify those misusing alcohol.

**Interview survey**

Mental health status was assessed using the Quick Personality Assessment Schedule (Tyrer, 2000), the Comprehensive Psychopathological Rating Scale (CPRS; Åsberg et al, 1978) and its sub-scales for rating depression (Montgomery–Åsberg Depression Rating Scale; Montgomery & Åsberg, 1979) and anxiety disorders (Brief Scale for Anxiety; Tyrer et al, 1984). All of the above assessments were applied to participants from both CMHT and substance misuse patient populations. Research psychiatrists assessed patients in the substance misuse group for psychosis using the Operational Checklist for Psychiatric Disorders (OPCRIT; McGuffin et al, 1991) based on a case-note review. A specificity analysis was conducted using information from the patient interview to ensure conservative rating of psychosis.

We used service-defined diagnoses to identify CMHT patients with psychosis. We completed OPCRIT assessments in a subsample of cases, enabling a specificity analysis to be completed; this showed that service-defined diagnosis was acceptable and reliable in identifying people with psychotic disorders (sensitivity 95%, specificity 81%). In our analysis the diagnostic category ‘psychosis’ included schizophrenia (F20.0–F20.9); schizotypal, schizoaffective, delusional and other unspecified psychotic disorders (F21–F29); manic episode with psychotic symptoms (F30.2); bipolar affective disorder (F31); severe depression with psychotic disorder (F32.3); and recurrent severe depression with psychotic symptoms (F33.3). The Alcohol Use Disorders Identification Test (AUDIT; Saunders et al, 1993) identified harmful (score ≥ 8) and severe (score ≥ 15) alcohol-related problems. A structured interview checklist identified drug types used (ever, past year, past month) and whether associated problems were present (economic, domestic, social, legal or interpersonal). Problem drug use was defined as self-reported presence of one or more of the above drug-related problems or care coordinator assessment of misuse. The Severity of Dependence Scale (Gossop et al, 1995) assessed drug dependency. These assessments were implemented in each treatment population.

To assess the reliability of self-reported drug use in CMHT patients we tested hair and urine samples, obtained from a random subsample of participants, by means of chromatography (Paterson et al, 2000) and mass spectrometry analysis (Paterson et al, 2001). Samples were obtained contemporaneously with self-report data. However, consent for hair and urine testing was obtained separately after each interview assessment.

**Analysis**

All analysis presented in this paper was undertaken with the interview samples achieved in each treatment population (Fig.1). The primary analysis calculated the proportions of each sample with comorbid conditions and the size of sub-populations defined in terms of psychiatric diagnosis and pattern of substance misuse. We then measured the proportions of comorbid cases that had been identified by keyworkers. By measuring the severity and types of comorbid disorder we identified approximate thresholds for access to each service. We used these data to assess the proportions of each treatment population with high or low potential for cross-referral and who had documented contact with both psychiatric and substance misuse services. All prevalence estimates are reported with exact binomial 95% confidence intervals. The statistical significance of observed differences in proportions was assessed using Pearson chi-squared or Fisher’s exact tests. These analyses were completed using SPSS (SPSS, 1999).

We then completed an extended quantitative analysis in relation to comorbid and non-comorbid sample groups in each treatment population. Multiple logistic regression was undertaken using cases with complete data on age, gender, ethnicity and diagnosis to investigate factors independently associated with comorbidity in the London centres. The aggregated Nottingham and Sheffield centres. Adjusted odds ratios with 95% confidence intervals were obtained and compared with the odds ratios from the univariate analysis. All variables were entered as categorical variables. Interactions between age group, gender, ethnicity, case-mix variables and location were investigated. The coding for ethnicity and age group was predetermined. The statistical package Stata 6.0 (StataCorp, 1999) was used for these latter analyses.

**RESULTS**

**Number and characteristics of participants**

We obtained data on 2528 of 2567 CMHT patients (98.5%) meeting census eligibility criteria (Fig. 1). Interviews were completed in 282 of 400 cases (70.5%) randomly sampled from this population. Sixty-eight of the patients interviewed were randomly pre-sampled for subsequent hair and urine testing, and 50 provided a sample (73.5%). Keyworkers provided data about 1645 of 1674 substance misuse service patients (98.3%) meeting census eligibility criteria. Complete interview and case-note data were obtained in 278 of 353 randomly selected cases (78.8%) (216 drug service patients, 62 alcohol service patients).

Treatment populations were predominantly male (57–67%). Men in contact with drug services and CMHTs had similar median ages (35 years and 36 years respectively) and age group distributions. Patients misusing alcohol were typically older (median age 42 years). In contrast, women in contact with drug services had a younger median age (32 years) than women in contact with alcohol services (39 years) or CMHTs (43 years). There were marked differences in ethnicity between patients comprising the drug and alcohol case-loads (> 90% White) and those of CMHTs (68.8% White, 23.8% Black).
Prevalence of comorbidity in drug and alcohol services

Three-quarters of drug service patients (n=161) rated positive for at least one psychiatric disorder (Table 3). A psychotic disorder was present in 17 patients (8%), personality disorder in 80 (37%) and severe depression in 58 (27%). The prevalence of all psychiatric disorders was markedly higher among alcohol service patients, although the small sample size means that the 95% confidence intervals for prevalence estimates are wide (Table 3).

Comparison of prevalence rates between centres

CMHT populations

Table 4 shows that a significantly higher proportion of CMHT patients from London centres reported problem drug use than those from Nottingham and Sheffield (42% vs 21%, $\chi^2=13.9$, d.f.=1, $P<0.001$). Patients reporting problem drug use in London centres (n=48) also reported past-year use of a higher number of drug types (mean=2.38) than drug-using patients in Nottingham and Sheffield (n=36; mean=1.65). Cannabis, sedatives/tranquillisers and crack cocaine use were all reported by a significantly higher proportion of patients in London centres than in Nottingham and Sheffield. The prevalence of any drug dependency was also significantly higher in patients from the London centres (25% vs 11%; $\chi^2=8.6$, d.f.=1, $P=0.005$).

Overall, there was a marked and statistically significant difference in proportions of patients reporting problem drug use and/or harmful alcohol use between London centres and Nottingham/Sheffield. This difference was mainly attributable to the higher reported prevalence of problem drug use in London, as there was no significant difference in the prevalence of harmful alcohol use between London centres and Nottingham/Sheffield.

We completed an extended multivariate analysis to investigate whether the observed differences in prevalence of drug use was explicable in terms of demographic analysis. This shows that virtually no unreported drug use was detected by hair and urine analysis. Although 18 respondents refused to provide samples, 4 of these reported drug use and there was no case in which care coordinators reported drug use that the patient denied.
COMORBIDITY OF SUBSTANCE MISUSE

Table I  Community mental health team study population (n=282): prevalence of self-reported harmful alcohol use, problem drug use and dependent drug use in the past year, and proportion of patients with substance misuse problems meeting referral thresholds for substance misuse services

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>(%)</th>
<th>Exact binomial 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Illicit or non-prescribed drug use (past year)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any drug use reported</td>
<td>87</td>
<td>(30.9)</td>
<td>25.5–36.6</td>
</tr>
<tr>
<td>Any drug use plus associated problems reported by keyworker and/or patient</td>
<td>84</td>
<td>(29.8)</td>
<td>24.5–35.5</td>
</tr>
<tr>
<td><strong>Frequency of reported use by drug type</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannabis</td>
<td>71</td>
<td>(25.2)</td>
<td>20.2–30.7</td>
</tr>
<tr>
<td>Sedatives/tranquillisers</td>
<td>21</td>
<td>(7.4)</td>
<td>4.7–11.2</td>
</tr>
<tr>
<td>Crack cocaine</td>
<td>16</td>
<td>(5.7)</td>
<td>3.3–9.1</td>
</tr>
<tr>
<td>Heroin</td>
<td>11</td>
<td>(3.9)</td>
<td>2.0–6.9</td>
</tr>
<tr>
<td>Ecstasy (3,4-methylenedioxyamphetamine)</td>
<td>11</td>
<td>(3.9)</td>
<td>2.0–6.9</td>
</tr>
<tr>
<td>Amphetamines</td>
<td>9</td>
<td>(3.2)</td>
<td>1.5–6.0</td>
</tr>
<tr>
<td>Cocaine</td>
<td>8</td>
<td>(2.8)</td>
<td>1.2–5.5</td>
</tr>
<tr>
<td>Opiate substitutes</td>
<td>4</td>
<td>(1.4)</td>
<td>0.4–3.6</td>
</tr>
<tr>
<td>Dependent use of illicit or non-prescribed drugs (SDS score ≥7)</td>
<td>47</td>
<td>(16.7)</td>
<td>12.5–21.5</td>
</tr>
<tr>
<td><strong>Frequency of dependent use of individual drug types</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannabis</td>
<td>36</td>
<td>(12.8)</td>
<td>9.1–17.2</td>
</tr>
<tr>
<td>Cocaine/crack cocaine</td>
<td>12</td>
<td>(4.3)</td>
<td>2.2–7.3</td>
</tr>
<tr>
<td>Heroin/opiates</td>
<td>6</td>
<td>(2.1)</td>
<td>0.8–4.6</td>
</tr>
<tr>
<td>Sedatives/tranquillisers</td>
<td>6</td>
<td>(2.1)</td>
<td>0.8–4.6</td>
</tr>
<tr>
<td><strong>Alcohol use (past year)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstinent</td>
<td>71</td>
<td>(25.2)</td>
<td>20.2–30.7</td>
</tr>
<tr>
<td>Non-harmful alcohol use (AUDIT &lt; 8)</td>
<td>139</td>
<td>(49.3)</td>
<td>43.3–55.3</td>
</tr>
<tr>
<td>Harmful use (AUDIT ≥ 8)</td>
<td>72</td>
<td>(25.5)</td>
<td>20.5–31.0</td>
</tr>
<tr>
<td><strong>Summary</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No harmful alcohol use or drug use reported</td>
<td>158</td>
<td>(56.0)</td>
<td>50.0–61.9</td>
</tr>
<tr>
<td>Harmful alcohol use or drug use reported</td>
<td>124</td>
<td>(44.0)</td>
<td>38.1–49.9</td>
</tr>
</tbody>
</table>

**Prevalence of comorbidity**

| Comorbid patients with low referral potential                  | 86 | (30.5) | 25.2–36.2 |
| Comorbid patients with high referral potential                 | 38 | (13.5) | 9.7–18.0  |
| **Illicit or non-prescribed drug use**                         |    |     |            |
| Opiate and/or cocaine/other stimulant dependence               | 15 | (4.3)  | 2.2–7.3   |
| Opiate dependence                                              | 6  | (2.1)  | 0.8–4.6   |
| Opiate dependence with injected drug use                       | 3  | (1.1)  | 0.2–3.1   |
| **Alcohol use**                                                |    |     |            |
| Severe alcohol problems (AUDIT score ≥ 15)                     | 26 | (9.2)  | 6.1–13.2  |

AUDIT: Alcohol Use Disorders Identification Test; SDS, Severity of Dependence Scale.

1. Aggregation of subgroup may exceed group totals owing to patients reporting polydrug use. Use of lysergic acid diethylamide (LSD), ketamine, methylphenidate, steroids, amyl nitrate or 'magic mushrooms' (psilocybin) reported in < 1% of cases. No reported use of solvents, gamma-hydroxybutyrate (GHB) or khat.
2. Harmful alcohol use, non-dependent problem drug use or dependent use of drugs other than opiates or stimulants.
3. Severe alcohol misuse or dependent use of opiates or stimulants.
4. Three patients appear in both subgroups of referable patients — i.e. they report severe alcohol problems (AUDIT score ≥15) and opiate and/or cocaine dependency or polydrug use.

variables (gender, ethnicity, age) and case-mix variables (presence of harmful alcohol use, psychiatric case-mix). This analysis revealed that the univariate odds ratio of problem drug use for patients on a London service case-load was 2.86 compared with Nottingham/Sheffield (95% CI 1.67–4.90). When the above variables were included in the multiple regression model we found that the adjusted odds ratio (AOR) of problem drug use in London centres over Nottingham/Sheffield was marginally reduced, but a large and statistically significant difference remained (AOR=2.52, 95% CI 1.31–4.85). Hence, a significant excess in problem drug use exists in the London centres compared with Nottingham and Sheffield which cannot be explained by controlling for the above variables.

We repeated this analysis to assess the association between reported harmful alcohol use in the past year using the same demographic (gender, ethnicity, age) and psychiatric case-mix variables but substituting ‘presence of drug use’ for ‘presence of harmful alcohol use’. The univariate odds ratio of harmful alcohol use for London CMHT patients was 1.18 compared with Nottingham and Sheffield (95% CI 0.68–2.04). However, as indicated by the confidence interval, the difference in odds is not statistically significant. When the above variables are included in the multiple regression model the adjusted odds ratio of alcohol misuse in London centres over Nottingham and Sheffield is reduced to a marginal level (AOR=1.05, 95% CI 0.52–2.11). Hence, this series of adjusted analyses showed statistically significant difference in prevalence of drug use between centres after adjustment for the selected case-mix variables. This contributes to a statistically significant difference in comorbidity (problem drug and/or harmful alcohol use). However, there is no evidence of a difference in the prevalence of harmful alcohol use between centres.

**Drug and alcohol services**

Table 4 compares the observed prevalence rates of psychiatric disorder in drug service patients between London centres and Nottingham/Sheffield. Despite a consistent pattern of marginally higher prevalence in London centres across the spectrum of disorders, there is no statistically significant difference in the proportions assessed to have one or more disorder, or a disorder within any of the three main subgroups assessed (psychosis, personality disorder, affective and anxiety disorder). We implemented an extended multivariate analysis to assess whether there was any difference in the odds of comorbidity between the London and Nottingham/Sheffield samples after adjustment for demographic (gender, ethnicity, age) and case-mix (presence of alcohol misuse, drug use profile) variables.

This analysis revealed that the univariate odds ratio of any psychiatric disorder for patients on a London service case-load was 1.47 (95% CI 0.77–2.80)
### Table 2
Validity assessment of self-reported drug use in community mental health team patients: comparison in matched subsample of 50 cases between self-reported drug use (past month) and use as detected by analysis of hair and urine samples

<table>
<thead>
<tr>
<th>Drug</th>
<th>Cases (n)</th>
<th>True negative (report and test negative)</th>
<th>True positive (report and test positive)</th>
<th>False negative (report negative, test positive)</th>
<th>False positive (report positive, test negative)</th>
<th>Results of statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td></td>
</tr>
<tr>
<td>Cannabis</td>
<td>49</td>
<td>39 (80)</td>
<td>9 (18)</td>
<td>0 0</td>
<td>1 (2)</td>
<td>Sensitivity 100%, specificity 97.5%; PPV 90%, NPV 100%</td>
</tr>
<tr>
<td>Ecstasy (3,4-methylenedioxy-methamphetamine)</td>
<td>50 47 (94)</td>
<td>0 0</td>
<td>0 0</td>
<td>0 0</td>
<td>3 (6)</td>
<td>Sensitivity 100%, specificity 94%; PPV 0%, NPV 100%</td>
</tr>
<tr>
<td>Amphetamines</td>
<td>50 49 (98)</td>
<td>1 (2)</td>
<td>0 0</td>
<td>0 0</td>
<td>0 0</td>
<td>Perfect (100%) agreement</td>
</tr>
<tr>
<td>Cocaine</td>
<td>50 49 (98)</td>
<td>1 (2)</td>
<td>0 0</td>
<td>0 0</td>
<td>0 0</td>
<td>Perfect (100%) agreement</td>
</tr>
<tr>
<td>Crack cocaine</td>
<td>50 50 (100)</td>
<td>0 0</td>
<td>0 0</td>
<td>0 0</td>
<td>0 0</td>
<td>Perfect (100%) agreement</td>
</tr>
<tr>
<td>Heroin</td>
<td>50 50 (100)</td>
<td>0 0</td>
<td>0 0</td>
<td>0 0</td>
<td>0 0</td>
<td>Perfect (100%) agreement</td>
</tr>
<tr>
<td>Methadone</td>
<td>50 50 (100)</td>
<td>0 0</td>
<td>0 0</td>
<td>0 0</td>
<td>0 0</td>
<td>Perfect (100%) agreement</td>
</tr>
<tr>
<td>Dipipanone hydrochloride</td>
<td>49 49 (98)</td>
<td>0 0</td>
<td>0 0</td>
<td>0 0</td>
<td>0 0</td>
<td>Perfect (100%) agreement</td>
</tr>
<tr>
<td>Dihydrocodeine tartrate</td>
<td>50 49 (98)</td>
<td>0 0</td>
<td>1 (2)</td>
<td>0 0</td>
<td>0 0</td>
<td>Sensitivity 0%, specificity 100%; PPV 100%, NPV 98%</td>
</tr>
<tr>
<td>Temazepam</td>
<td>6 6</td>
<td>50 (98)</td>
<td>15 (2.0)</td>
<td>2 (4)</td>
<td>0 0</td>
<td>Sensitivity 33%, specificity 100%; PPV 100%, NPV 95.9%</td>
</tr>
</tbody>
</table>

NPV, negative predictive value; PPV, positive predictive value.

1. There was no self-reported use in this sample of the following substances: solvents, gamma-hydroxybutyrate, lysergic acid diethylamide, 'magic mushrooms' (psilocybin), steroids or anabolic steroids, methylphenidate, khat, ketamine, dextromoramide or buprenorphine. However, this was not verifiable by the hair or urine analysis available. Use of amyl nitrite was reported in one case but was also not verifiable by the available hair or urine analysis.

2. Cannabis and dipipanone are only detectable in urine. Hence, the presence of these drugs was not assessed in one case where a patient provided a hair sample but refused to provide urine.

3. This patient reported using £5 worth of cannabis (type/grade unknown) 2 days a week over the month prior to testing. This was a lower level of consumption than all the other patients who tested positive. However, the reported level of consumption should have been sufficient for the metabolite to be detectable in the urine.

4. Patients all reported use 1 day per week over the month prior to testing, consuming one to four ecstasy tablets. In one case a hair sample was not available for analysis. Ecstasy is only detected in urine for 1–2 days, so the negative result might well be because the urine sample was not obtained soon enough after ingestion. This would be a likely explanation if use were recreational at weekends. Hair samples were available in the other two cases; these patients tested positive for cocaine and amphetamine respectively, so it is likely that ecstasy would have been detected if present.

5. This patient did not report use of dihydrocodeine at any time, but did report current use of temazepam and tested positive for this. It is possible that the positive dihydrocodeine result detected use of prescribed pain relief medication.

### Potential for cross-referral of patients

#### CMHT patients

Just six of the CMHT patients were opiate-dependent and had a high referral potential for statutory opiate-based drug treatment services. An additional nine patients reported crack cocaine or other stimulant dependence and would potentially qualify for brief intervention or referral to stimulant clinics (if available). Although significant additional numbers were cannabis-dependent, these patients are unlikely to meet referral criteria applied by routinely available drug services. (No drug service patient was dependent solely on cannabis in our sample.) The potential for referral to alcohol services appears to be greater, given that almost a tenth of patients (n=26) reported severe alcohol misuse (i.e. AUDIT score >15; Table 1).

### Substance misuse service patients

Non-substance-related psychotic disorder was identified in 17 drug service patients and 12 alcohol service patients. All exhibited 'complex care needs' and recorded high CPRS scores (median for drug service patients 22, range 0–42; median for alcohol service patients 32, range 13–54) relative to psychiatric service patients with a psychotic disorder (median 8, range 0–38). Hence they were likely to have high referral potential to CMHTs for enhanced CPA management. A further 10–13% in each population had severe depression and 'complex care needs', which might have made them candidates for CMHT management. Thus, in total, 39 drug service patients (18%) and 20 alcohol service patients (32%) appeared to have a high potential for CMHT referral (see Table 3).

### Identification and management of comorbidity

We compared comorbidity reported by care coordinators and key workers with the...
relevant reference assessments obtained at interview. Patients without comorbidity were generally correctly identified as such by services (specificity > 90%). However, substance misuse service patients with psychiatric disorders and CMHT patients reporting harmful alcohol use were mostly unrecognised (sensitivity 20–38%). Only in relation to CMHT patients reporting (any) drug use did care coordinators achieve moderately good sensitivity (60%) (Table 5).

Small minorities of CMHT patients with comorbidity had received alcohol- or drug-related interventions in the month prior to assessment – 15 of 72 reporting harmful alcohol use (21%) and 14 of 84 reporting problem drug use (17%) – mostly counselling provided through the CMHT. Seven patients had contact with specialist drug or alcohol services. More patients with high referral potential (as defined above) received substance misuse interventions, but interventions were more likely to be provided to patients with either high or low referral potential if a care coordinator identified the comorbidity problem. For example, 11 of 14 CMHT patients with identified severe alcohol problems received interventions compared with 1 of the 12 whose severe problems were undetected.

More than a fifth of drug and alcohol services patients with comorbidity (48 of 214) had contact with psychiatric services, of whom 26 (12%) were allocated to CMHT management during the previous month. Patients with 'high' referral potential were significantly more likely to have contact with psychiatric services than those rated 'low' (35/59, 59% v. 13/155, 8%; \( \chi^2 = 60.8, d.f. = 1, P < 0.001 \)). Some patients with comorbidity reported consultations with a psychiatrist in the substance misuse service (n = 41, 19%) or with a general practitioner (n = 57, 27%) about their mental health problems, but 32% (n = 68) received no intervention. Most of the latter were patients with undetected, 'low referral potential' problems (48/68, 71%).

**DISCUSSION**

**Study limitations**

Certain study limitations should be acknowledged. First, we assessed comorbidity within current treatment populations, which tend to include more complex cases; therefore, findings are not generalisable to the same diagnostically defined groups within the general population. Second, given our sample sizes, some prevalence estimates lack precision. Third, the study compares the prevalence of comorbidity in samples drawn from two urban centres in London and from Nottingham and Sheffield. Although the study represents an advance on previous single-centre studies and highlights the potential for variability in prevalence, we need to exercise caution in our interpretation of these findings. We make no claim that Nottingham and Sheffield are representative of urban areas outside London. Similarly, it is important to note that the London centres were both inner-city ones and not representative of London as a whole. People in inner London with severe mental illness have rates of geographical mobility that are twice as high as those for outer London. This may help account for higher psychiatric morbidity (Lamont et al., 2000). Further investigation in more regions would be required before any definitive picture emerges about regional variation in prevalence.

Despite these limitations, the study provides strong evidence that comorbidity
### Table 4: Comparison between London centres and Nottingham/Sheffield in the prevalence of comorbidity: prevalence of self-reported problem drug use and harmful alcohol use in the past year in community mental health team patients, and prevalence of psychiatric disorders (psychosis, personality disorder, affective/anxiety disorder) in drug service patients

<table>
<thead>
<tr>
<th>Disorder Present</th>
<th>London centres</th>
<th>Nottingham and Sheffield</th>
<th>$\chi^2$ (d.f.)</th>
<th>$P$</th>
<th>Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>n (%)</td>
<td></td>
<td></td>
<td></td>
<td>n (%)</td>
</tr>
</tbody>
</table>

#### Community mental health team patients

**Sample size (n):**

- **Illicit or non-prescribed problem drug use (past year):**
  - No problem drug use reported: 66 (58)
  - Problem drug use reported: 48 (42)

**Frequency of reported use by drug type (past year):**

- **Cannabis:** 41 (36) 30 (18) 11.8 (1) 0.001 71 (25)
- **Sedatives/tranquillisers:** 19 (17) 2 (1) 23.6 (1) <0.001 21 (7)
- **Crack cocaine:** 11 (10) 5 (3) 5.7 (1) 0.03 16 (6)
- **Heroin:** 7 (6) 4 (2) 2.6 (1) 0.1 11 (4)
- **Ecstasy (3,4-methylenedioxymethamphetamine):** 6 (5) 5 (3) 0.95 (1) 0.4 11 (4)
- **Amphetamines:** 4 (4) 5 (3) 0.06 (1) 1.0 9 (3)
- **Cocaine:** 6 (5) 2 (1) 4.1 (1) 0.07 8 (3)
- **Opiate substitutes**: 3 (3) 1 (1) 0.79 (1) 0.3 4 (1)

**Dependent use of illicit or non-prescribed drugs (past year):**

- No dependent drug use: 86 (75)
- Dependent drug use (AUDIT score >7): 28 (25)

**Frequency of dependent use by drug type (past year):**

- **Cannabis:** 22 (19) 14 (8) 6.38 (1) 0.01 36 (13)
- **Cocaine/crack cocaine:** 8 (7) 4 (2) 2.54 (1) 0.07 12 (4)
- **Heroin/opiates:** 4 (4) 2 (1) 0.82 (1) 0.2 6 (2)
- **Sedatives/tranquillisers:** 3 (3) 3 (2) 0.2 (1) 0.07 6 (2)
- **Stimulants:** 2 (2) 5 (3) 0.07 (1) 0.8 7 (3)

**Hazardous or harmful alcohol use (past year):**

- **Abstinent or non-harmful alcohol use (AUDIT <8):** 83 (73) 127 (75.6) 0.3 (1) 0.6 210 (75)
- **Harmful use (AUDIT >8):** 31 (27) 41 (24.4) 0.3 (1) 0.6 72 (26)

**Summary:**

- **No alcohol misuse or drug use reported:** 53 (47) 105 (63)
- **Alcohol use reported:** 61 (54) 63 (38) 7.06 (1) 0.01 124 (44)

#### Drug service patients

**Sample size (n):** 85 131 216

**Non-substance-induced psychotic disorders:**

- **No disorder:** 76 (90) 123 (94) 199 (92)
- **Disorder present:** 8 (11) 8 (6) 1.4 (1) 0.3 17 (8)
- **Schizophrenia:** 3 (4) 3 (2) 6 (3)
- **Bipolar affective disorder, psychotic depression:** 1 (1) 0 (1)
- **Non-specific psychosis:** 5 (6) 5 (4) 2.4 (3) 0.49 10 (5)

**Personality disorder:**

- **No disorder:** 49 (58) 87 (66) 136 (63)
- **Disorder present:** 36 (42) 44 (34) 1.7 (2) 0.19 80 (37)

**Affective and/or anxiety disorder:**

- **No disorder reported:** 25 (29) 45 (34) 70 (32)
- **Diagnosis reported**: 60 (71) 86 (66) 0.76 (1) 0.45 146 (68)
- **Affective disorder not present:** 25 (29) 46 (35) 71 (33)
- **Affective disorder present:** 60 (71) 85 (65) 0.76 (1) 0.46 145 (67)
- **Mild depression:** 37 (44) 50 (38) 87 (40)
- **Severe depression:** 23 (27) 35 (27) 0.88 (2) 0.64 58 (27)
- **No severe anxiety disorder present:** 70 (82) 105 (80) 175 (81)
- **Severe anxiety disorder present:** 15 (18) 26 (20) 0.16 (1) 0.69 41 (19)

**Summary:**

- **No disorder:** 18 (21) 37 (28) 55 (26)
- **Psychiatric disorder or symptoms indicative of disorder**: 67 (79) 94 (72) 1.4 (2) 0.27 161 (75)

---

**Notes:**

1. Aggregation of subgroup may exceed group totals owing to patients having more than one disorder.

2. Patients were asked specifically about methadone, dexamphetamine, diphendydramine tartrate, diphenoxylate hydrochloride and bupropion.

3. Aggregation of subgroup exceeds group totals owing to patients reporting polydrug use.

**AUDIT:** Alcohol Use Disorders Identification Test; SDS, Severity of Dependence Scale.
is highly prevalent in CMHT, drug and alcohol treatment populations. Our findings relating to the profile and management of comorbidity also have major implications for service development.

**Prevalence and pattern of comorbidity**

Overall, 44% of CMHT patients reported past-year problem drug use and/or harmful alcohol use. This is higher than previously observed in comparable UK populations using similar assessment methods (33–36%) and is largely accounted for by a higher level of drug use than previously reported (Menezes et al., 1996; Wright et al., 2000; Duke et al., 2001). Hair and urine analysis revealed no significant covert drug use and suggested that these self-reported drug use data provide a reliable and valid basis for prevalence estimation. Given that consent for obtaining hair and urine samples was separate from and subsequent to interviews, we can exclude the possibility that patients were more accurate in reporting drug use because they knew they were to be tested. The prevalence of harmful alcohol use among CMHT patients (26%) is consistent with previous estimates (20–32%) using self-reported measures (Menezes et al., 1996; Wright et al., 2000; Duke et al., 2001).

Findings in relation to the level of problem drug use are even more striking when the differences between centres are considered. In the London centres, 42% of CMHT patients reported problem drug use and 25% were assessed as drug dependent. Overall, more than half of London CMHT patients reported substance misuse problems in the past year. We stress the importance of cautious interpretation of these findings, but nevertheless this does appear to confirm the view that patients with such comorbidity may represent the core client group of CMHTs in certain inner-city areas, where the prevalence may be dramatically high (Banerjee et al., 2002).

Large majorities of patients treated for drug and alcohol misuse experience psychiatric disorder, although there was no suggestion that these rates differed significantly between centres in our study. Our estimates for the prevalence of severe depression and personality disorder are consistent with other studies of comparable populations (Regier et al., 1990; Verheul, 2001). However, the prevalence of psychosis (drug service patients 8%, alcohol service patients 19%) was significantly higher than previously reported (Regier et al., 1990) and was 10 times (drug) and 24 times (alcohol) the prevalence rate for psychosis in the urban UK population (0.8%; Jenkins et al., 1998).

**Implications for management**

In each population studied, comorbid presentations were heterogeneous. Responding to the level and range of need will be challenging given associated clinical management problems (Scott et al., 1998;
Implications for service development and future research

It is evident that ‘parallel’ or ‘serial’ treatment by independent and substance misuse services and CMHTs (as currently configured) cannot meet the level and range of need presented by comorbid populations. Integrated treatment teams – favoured in the USA to provide treatment for both types of disorders without cross-referral (Drake et al., 1995) – lack a strong evidence base (Ley et al., 1999) and may not be appropriate or replicable in UK settings (Hall & Farrell, 1997; Johnson, 1997; Weaver et al., 1999). Moreover, there is a danger that the development of integrated teams could result in drug and alcohol services remaining underresourced and narrowly focused (i.e. upon opiate use, in the case of drug services). Instead, we support current efforts to develop the capacity and competency of ‘mainstream’ services (Banerjee et al., 2002).

Drug and alcohol treatment services already provide mental health interventions (both pharmacological and psychotherapeutic) to significant numbers of their patients with mental health problems. However, there were equally large numbers of patients with comorbidity whose needs were unmet or unidentified. Resources need to be deployed enabling substance misuse services to offer evidence-based treatments to a much higher proportion of these patients (Hall & Farrell, 1997). Models of collaborative working with local general practitioners and psychotherapy services (in addition to general adult psychiatry) should be developed and evaluated. In relation to CMHTs, our findings suggest that mainstream staff need to be able to implement at least basic management of comorbidity. To achieve this, staff are likely to need enhanced training in the assessment of drug and alcohol problems (and in the use of appropriate evaluation tools), as well as motivational techniques to improve patient engagement with substance misuse treatment and achieve harm minimisation goals. Interventions to address these skill deficits require urgent evaluation.

Although enhanced training has rightly been identified as a key component of our response to comorbidity (Banerjee et al., 2002), there is also a need to resource, develop and evaluate new service-based assessment, treatment and management approaches, which can support psychiatric and substance misuse services in offering evidence-based treatments to much higher proportions of their patients with problems of comorbidity.

ACKNOWLEDGEMENTS

The authors of this work received funding under the Department of Health’s Drug Misuse Research Initiative. The views expressed in this publication are those of the authors and not necessarily those of

CLINICAL IMPLICATIONS

- Comorbidity of psychiatric disorders and substance misuse is highly prevalent in those receiving treatment for one of these conditions.
- Psychiatric teams and substance misuse services fail to identify significant proportions of patients with such comorbidity on their case-loads. Most patients with substance misuse problems on psychiatric case-loads receive no substance misuse interventions, and a third of substance misuse patients with mental health problems do not receive any mental health interventions.
- Comorbidity cannot be adequately managed by cross-referral between psychiatric and substance misuse services as currently configured and resourced. A new approach is needed to enable psychiatric and substance misuse services to offer evidence-based treatment of comorbid conditions to a much higher proportion of their patients.

LIMITATIONS

- Because comorbidity was assessed within treatment populations, findings are not generalisable to the same diagnostically defined groups within the general population.
- Some prevalence estimates lack precision owing to small sample sizes.
- We found significant differences in the prevalence of drug use among psychiatric patients in different centres, but evidence from more centres is required before firm conclusions about regional differences in prevalence are made.
the sponsors. The authors express their gratitude to the funders for supporting this work. The Centre for Research on Drugs and Health Behaviour is core funded by the London Regional Office of the National Health Service Executive.

The COSMID study group consists of the following members: Imperial College, London: Tim Weaver, Vikki Charles, Zenobia Carnwath, Peter Madden, Adrian Renton, Gerry Stimson, Peter Tyer; Thomas Barnes, Chris Bench and Susan Paterson; Turning Point, Brent: Chris Ford; Central and North West London Mental Health NHS Trust: Jonathon Greenside, Owen Bowden Jones and William Shanahan; Community Health Sheffield NHS Trust: Helen Bourne, Muhammad Z. Iqbal and Nicholas Seivewright; Nottingham Healthcare NHS Trust: Sylvia Cooper, Katina Anagnostakis, Hugh Middleton and Neil Wright.

REFERENCES


Comorbidity of substance misuse and mental illness in community mental health and substance misuse services


Access the most recent version at DOI: 10.1192/bjp.183.4.304

References
This article cites 25 articles, 9 of which you can access for free at: http://bjp.rcpsych.org/content/183/4/304#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at /letters/submit/bjprcpysch;183/4/304

Downloaded from http://bjp.rcpsych.org/ on October 13, 2017
Published by The Royal College of Psychiatrists

To subscribe to The British Journal of Psychiatry go to: http://bjp.rcpsych.org/site/subscriptions/